| Literature DB >> 22568881 |
Maria Raffaella Ambrosio1, Bruno Jim Rocca, Alessandro Ginori, Monica Onorati, Alberto Fabbri, Mario Carmellini, Stefano Lazzi, Sergio Tripodi.
Abstract
Angioimmunoblastic T-cell lymphoma is one of the most common subtypes of peripheral T-cell lymphoma (15-20% of all cases), accounting for approximately 1-2% of all non-Hodgkin lymphomas. It often presents autoimmune phenomena including hemolytic anemia, thrombocytopenia, glomerulonephrities and circulating immune complexes. Polyarteritis nodosa is an autoimmune disease characterized by necrotizing vasculitis of medium vessels, which rarely develops in association with hematological malignant disorders. Herein we report the case of a 40-year-old man who underwent lymph node biopsy in the suspicious of sarcoidosis. On the basis of histological and immunohistochemical findings, the diagnosis of angioimmunoblastic T-cell lymphoma was performed. The patient was successfully treated with cytarabine-based regimen for 6 cycles. Three months after the initial diagnosis of angioimmunoblastic T-cell lymphoma, a whole body computed tomography showed a lesion in the lower pole of the left kidney. Renal cell carcinoma was suspected, thus a nephrectomy was carried out. The histological findings were compatible with polyarteritis nodosa. To the best of our knowledge, the association between polyarteritis nodosa and angioimmunoblastic T-cell lymphoma has been described only once. This relation may be secondary to the induction of an autoimmune phenomenon by the lymphoma with the formation of circulating immune complexes, leading to vessels walls injury. A careful evaluation is needed in the management of angioimmunoblastic T-cell lymphoma patients with signs of renal failure in order to avoid delay of treatment and organ damage.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22568881 PMCID: PMC3487756 DOI: 10.1186/1746-1596-7-50
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Summary of laboratory data
| Hb | 12,2 g/dl | 14-18 g/dl |
| RBC | 5,3 × 106/mm3 | 4,5-6 × 106/mm3 |
| WBC | 6,6 × 103/mm3 | 4-8 × 103/mm3 |
| Hematocrit | 45% | 40-52% |
| MCV | 90 μm3 | 83-93 μm3 |
| MCHC | 34 g/dl | 32-36 g/dl |
| Platelet count | 225 × 103/mm3 | 150-350 × 103/mm3 |
| AST | 10 UI/l | 0-35 UI/l |
| ALT | 10 UI/l | 0-35 UI/l |
| LDH | 552 U/l | 120-240 U/l |
| Total protein | 8,6 g/dl | 6,5-8,0 g/dl |
| Albumin | 42,3 g/l | 35,2-50,4 g/l |
| β2-microglobulin | 5.2 mg/dL | 0,1-0,2 mg/dL |
| Blood urea nitrogen | 32 mg/dl | 10-50 mg/dl |
| Creatinine | 0,9 mg/dl | 0-1,3 mg/dl |
| Blood glucose | 96 mg/dl | 70-110 mg/dl |
| C-reactive protein | 35 mg/l | 0-5 mg/l |
| ACE | 15 U/l | < 40 U/l |
| IgA | 1150 mg/dl | 90-450 mg/dl |
| IgG | 2245 mg/dl | 80-1800 mg/dl |
| IgM | 135 mg/dl | 60-250 mg/dl |
Hb Haemoglobin, RBC red blood cells count, WBC white blood cells count, MCV mean corpuscular volume, MCHC mean cell haemoglobin concentration, AST serum aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, ACE angiotensin converting enzyme.
Figure 1TC scan findings. A lesion of 45 mm in the upper pole of the left kidney is shown.
Figure 2Axillary lymph node morphology. Effacement of lymph node architecture with burnt-out follicles (A) and marked vascular proliferation (B) was observed. The neoplastic cells show clear-to-pale cytoplasm, distinct cell membrane and minimal atypia (C); they mainly express CD4 (D). EBV-positive B cells are present (inset, D). [A-C: Haematoxylin–Eosin (H&E); Original Magnification (O.M.): 40x; D: CD4 stain, O.M.: 40x; D, inset: EBER in situ hybridization, O.M.: 40x.
Figure 3Renal infarction. Gross morphology shows a large pale lesion of the lower pole (A). Histological examination shows coagulative necrosis of renal parenchyma (B), aneurysmal distension of the arterial wall (C) and rupture of the internal elastic lamina (C, inset, arrow). Some vascular lumina are obliterated by fibrous stroma and recanalized by thin vascular channels (D). (B-D: Masson stain; O.M.: 40x; 20x; 40x).
Clinicopathological features of patients with AITL developing renal involvement
| Wood and Harkins [ | M | 76 | Diffuse proliferative glomerulonephritis | 0 | Corticosteroid, cyclophosphamide | Dead for lymphoma |
| Wood and Harkins [ | M | 79 | Minimal change disease | 0 | Dialysis | Dead for renal failure |
| Bhat et al [ | F | 77 | Acute renal failure with Bence-Jones proteinuria | 4 | None | Dead for sepsis |
| Platzer et al [ | M | 64 | Renal failure | 0 | Prednisolone | CR |
| Bello et al [ | M | 61 | Fanconi syndrome | 0 | Hydrocortisone | CR |
| Bignon et al [ | M | 70 | Dysproteinaemia | 0 | n.a. | n.a. |
| Yamazaki et al [ | M | 72 | Endocapillary proliferative glomerulonephritis | 0 | Vincristine, prednisolone | Dead for alimentary tract bleeding |
| Nakamoto et al [ | M | 40 | Acute interstitial nephritis | 16 | Prednisolone, cyclophosphamide | At 60-month follow-up, no signs of relapse |
| Duwaji et al [ | M | 71 | Proliferative glomerulonephritis | 2 | CHOP regimen | Dead for sepsis |
| Lim et al [ | M | 33 | Amyloidosis | 12 | CHOP regimen | At 12-month follow-up, no signs of relapse |
| Hamidou et al [ | M | 56 | Vasculitis | 0 | CHOP regimen | Dead for renal failure |
| De Samblanx et al [ | M | 67 | Proliferative glomerulonephritis | 0 | CHOP regimen | At 12-month follow-up, no signs of relapse |
| Goto et al [ | M | 73 | Direct invasion by lymphoma | 0 | CHOP regimen | At 20-month follow-up, no signs of relapse |
| Miura et al [ | M | 70 | IgM-λ glomerular thrombi | 2 | CHOP regimen | At 3-month follow-up, no signs of relapse |
| Tagashi et al [ | M | 21 | Nephrotic syndrome | 0 | CHOP regimen | At 36-month follow-up, no signs of relapse |
CR complete remission; n.a. not available, CHOP Cyclophosphamide, doxorubicin, vincristine, prednisolone.